Multicolor flow cytometric assessment of Ki67 expression and its diagnostic value in mature B-cell neoplasms
Open Access
- 17 February 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1108837
Abstract
Background: There is no unified standard data about the sensitivity and specificity regarding flow cytometry analysis of Ki67 expression during lymphoma diagnoses.Objective: This evaluated the efficacy of multicolor flow cytometry (MFC) in an estimate of the proliferative activity of B-cell non-Hodgkin lymphoma by comparing the expression of Ki67 using MFC and immunohistochemicals (IHC).Method: A total of 559 patients with non-Hodgkin B-cell lymphoma were immunophenotyped using sensitive MFC, of which 517 were newly diagnosed and 42 were transformed lymphomas. Test samples include peripheral blood, bone marrow, various body fluids, and tissues. Through MFC multi-marker accurate gating, abnormal mature B lymphocytes with restricted expression of the light chain were screened. Ki67 was added to determine the proliferation index; the positive rate of Ki67 in tumor B cells was evaluated by cell grouping and internal control. For tissue specimens, MFC and IHC analyses were performed simultaneously to assess the Ki67 proliferation index.Results: The positive rate of Ki67 by MFC was correlated with the subtype and aggressiveness of B-cell lymphoma. Ki67 could distinguish indolent lymphomas from aggressive subtypes with a cut-off value of 21.25%, and differentiate transformation from indolent lymphoma with a cut-off value of 7.65%. The expression of Ki67 by MFC (regardless of the type of samples)was highly agreement with the Ki67 proliferative index of tissue samples assessed by pathologic immunohistochemistry. MFC showed a fairly constant negative bias in evaluating tissue or bone marrow samples, compared with IHC.Conclusions: Ki67 is a valuable flow marker that can distinguish between indolent and aggressive types of lymphoma and assess whether indolent lymphomas are transformed. Using MFC to evaluate the positive rate of Ki67 is important in clinical settings. MFC has unique advantages in judging the aggressiveness of lymphoma in samples of bone marrow, peripheral blood, pleural and ascites, and cerebrospinal fluid. This is particularly important when tissue samples cannot be obtained, making it an important supplement for pathologic examination.Keywords
Funding Information
- National Natural Science Foundation of China
This publication has 42 references indexed in Scilit:
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood, 2011
- Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL NetworkJournal of Hematopathology, 2009
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaBlood, 2008
- Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic IndexBlood, 2007
- 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasiaCytometry Part B: Clinical Cytometry, 2007
- The Usefulness of CD71 Expression by Flow Cytometry for Differentiating Indolent From Aggressive CD10+ B-Cell LymphomasAmerican Journal of Clinical Pathology, 2006
- Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki‐67 expressionPathology International, 2004
- The Ki-67 protein: From the known and the unknownJournal of Cellular Physiology, 2000
- Proliferating cell nuclear antigen and Ki‐67 antigen expression in human haematopoietic cells during growth stimulation and differentiationCell Proliferation, 1993
- Expression of Proliferating Cell Nuclear Antigen (PCNA) and Ki-67 Antigen in Human Malignant Hematopoietic CellsActa Oncologica, 1991